|Healthcare Review: Prana Biotechnology Limited, Osiris Therapeutics, Anacor Pharmaceuticals, MannKind Corporation, ZIOPHARM Oncology|
|By Staff and Wire Reports|
|Friday, 16 August 2013 13:05|
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) stock jumped 10.99% to $4.14. The company on July 3 announced that it has received approval from the Austin Health Human Research Ethics Committee (HREC) to commence a 12-month open-label extension study with Alzheimer's Disease patients participating in Prana's IMAGINE trial. The approval follows a full review by Austin Health HREC of the potential benefit to patients and safety data collected during the ongoing IMAGINE trial, a 12-month double-blind Phase II clinical trial of PBT2 in Alzheimer's patients.
Osiris Therapeutics, Inc. (NASDAQ:OSIR) stock jumped 9.72% to $21.52. The company on August 13 said its Grafix stem-cell treatment for chronic diabetic foot ulcers met primary and secondary endpoints in a recent clinical trial that compared the product with conventional treatment. The study included 131 diabetes patients who received weekly applications of Grafix or conventional treatment. In the trial, 62% of patients receiving Grafix had complete wound closure compared with only 21% of patients who received conventional treatment.
Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) shares gained 8.56% to $11.29. The company, on August 8, announced its financial results for the second quarter ended June 30, 2013. Revenues for the quarter ended June 30, 2013 were $3.4 million, compared to $2.6 million for the comparable period in 2012. Cash, cash equivalents, short-term investments and restricted investments totaled $51.1 million, including restricted investments of $5.3 million, at June 30, 2013.
MannKind Corporation (NASDAQ:MNKD) shares dropped 6.66% to $6.20. The company on August 14 announced positive preliminary results from Study 171, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation (Gen2) inhaler (also known as the Dreamboat™ inhaler), in patients with type 1 diabetes.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares decreased 3.57% to $2.97. The company issued its quarterly earnings data on August 9. The company reported ($0.22) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.24) by $0.02. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. During the same quarter in the prior year, the company posted ($0.29) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis.